Asia Pacific Cancer Biological Therapy Market Information: By Type (Monoclonal Antibodies, Interferons, Interleukins, Cancer Growth Inhibitors, Gene Therapy, Colony-Stimulating Factors, Targeted Therapy, Cancer Vaccines and others), By Phases (Phase I, Phase II, Phase III) By End Users (Hospitals & Clinics, Cancer Research Centers, Laboratories) - Forecast till 2027
ID: MRFR/Pharma/2980-HCR | February 2021 | Region: Global | 50 Pages
Table of Contents
1 Report Prologue
2 Market Introduction
2.1 Introduction
2.2 Scope of Study
2.3 Research Objective
2.4 Assumptions & Limitations
2.4.1 Assumptions
2.4.2 Limitations
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
4 Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
5 Market Factor Analysis
5.1 Porter’s Five Forces Model
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Supply Chain Analysis
6. Asia Pacific Cancer Biological Therapy Market, by Type
6.1 Monoclonal Antibodies
6.2 Interferons
6.3 Interleukins
6.4 Cancer Growth Inhibitors
6.5 Gene Therapy
6.6 Colony-Stimulating Factors
6.7 Targeted Therapy
6.8 Cancer Vaccines
6.9 Others
7. Asia Pacific Cancer Biological Therapy Market, by Phases
7.1 Phase I
7.2 Phase II
7.3 phase III
8. Asia Pacific Cancer Biological Therapy Market, by Phases
8.1 Hospitals & Clinics
8.2 Cancer Research Centers
8.3 Laboratories
8.4 Others
9. Asia Pacific Cancer Biological Therapy Market, by Regions
9.1 Introduction
9.1.1 Japan
9.1.2 China
9.1.3 India
9.1.4 Australia
9.1.5 Republic of Korea
9.1.6 Rest of Asia Pacific
10. Competitive Landscape
10.1 Major Strategies Adopted By Market Players
10.1.1 Strategic Partnership
10.1.2 Merger & Acquisition
11 Company Profile
11.1 Merck & Co., Inc.
11.1.1 Overview
11.1.2 Product Overview
11.1.3 Financials
11.1.4 Key Developments
11.2 F. Hoffmann-La Roche Ltd
11.2.1 Overview
11.2.2 Product Overview
11.2.3 Financials
11.2.4 Key Developments
11.3 Novartis AG
11.3.1 Overview
11.3.2 Product Overview
11.3.3 Financials
11.3.4 Key Development
11.4 Amgen Inc.
11.4.1 Overview
11.4.2 Product Overview
11.4.3 Financials
11.4.4 Key Developments
11.5 Bristol-Myers Squibb
11.5.1 Overview
11.5.2 Product Overview
11.5.3 Financials
11.5.4 Key Developments
11.6 Celgene
11.6.1 Overview
11.6.2 Product Overview
11.6.3 Financials
11.6.4 Key Developments
11.7 Eli Lilly and Company
11.7.1 Overview
11.7.2 Product Overview
11.7.3 Financials
11.7.4 Key Developments
11.8 EnGeneIC
11.8.1 Overview
11.8.2 Product Overview
11.8.3 Financials
11.8.4 Key Developments
11.9 Intas Pharmaceuticals Ltd.
11.9.1 Overview
11.9.2 Product Overview
11.9.3 Financials
11.9.4 Key Developments
11.10 Others
12 Conclusion
12.1 Key Findings
12.1.1 From CEO’s Viewpoint
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of Pharmaceutical Industry
13 Appendix
Asia Pacific Cancer Biological Therapy Market
Asia Pacific cancer biological therapy market is expected to grow at a CAGR of 7.7% during the forecasted 2022-2030
$172.45 Billion
Market Size
7.7%
CAGR
Asia Pacific
Dominating Region
2022-2030
Forecast Period
Segmentation
Key Players
- Merck & Co.Inc. (US)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Novartis AG (Switzerland)
- Amgen Inc. (US)
- Bristol-Myers Squibb (US)
- Celgene (US)
- Eli Lilly and Company (US)
- EnGeneIC (Australia)
- Pfizer (US)
- Intas Pharmaceuticals Ltd. (India)
- Sun Pharmaceutical Industries Ltd. (India)
Drivers
- increasing cancer survival rates
- growing demand for advanced therapies such as biological therapy
Market Scenario Cancer is the leading and the second largest cause of death across the globe. The disease is characterized by disordered and deregulated cellular and stromal explosion along with reduced cell death and growth factor deprivation, and others. Biological therapy treatment is done with the help of living organisms, parts of living organisms or laboratory manufactured version of such content. Various types of biological therapies, which inhibit specific molecules involved in development and growth of cancer tumor, such therapies known as; cancer targeted therapies.
The major driving factors for Asia Pacific cancer biological therapy market are increasing cancer survival rates, growing demand for advanced therapies such as biological therapy, growth of cancer healthcare facilities in emerging countries, etc. Additionally, less number of side effects associated with biological therapy as compared to conventional treatment methods is the critical growth factor. Conventional cancer treatment methods like chemotherapy, radiotherapy give effective result, but along with that these methods also show its counter effects on body. The side effects may include, loss of hair, weakened immune system, and such others depending upon the type, and phase of cancer. Biological therapies help to reduce the level of side effects as compared to other treatment methods. Biological therapies are giving the same amount of success rate for curing the cancer patient with 1st stage cancer approximately 27% to 35%. Owing to low level of side effects and high success rate of this therapy, the market is expected to grow rapidly. However, high cost of the treatment may restrain the market growth.
The Asia Pacific cancer biological therapy market is expected to grow at a CAGR of 5.5% during the forecasted period. Figure 1: Asia Pacific cancer biological therapy market, by types
Sources: Annual reports, Press release, White paper, Company Presentation
Key Players The leading market players in the Asia Pacific cancer biological therapy market include Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Amgen Inc. (US), Bristol-Myers Squibb (US), Celgene (US), Eli Lilly and Company (US), EnGeneIC (Australia), Pfizer (US), Intas Pharmaceuticals Ltd. (India), and Sun Pharmaceutical Industries Ltd. (India)
Segmentation Asia Pacific cancer biological therapy market is segmented into types, phases, and end users.
On the basis of types the market is segmented into monoclonal antibodies, interferon, interleukins, cancer growth inhibitors, gene therapy, colony-stimulating factors, targeted therapy, cancer vaccines, and others. On the basis of phases, the market is segmented into phase I, phase II, and phase III.
On the basis of end users, the market is segmented into hospitals & clinics, cancer research centers, laboratories, and others.
Market Assessment 
Sources: Annual reports, World Health Organization (WHO), White paper, Company Presentationa
Regional Analysis China dominates the Asia Pacific cancer biological therapy market owing to increasing prevalence of cancer. Increasing adoption of smoking by people, rapid research & development and presence rapidly developing economy in this region fuel the growth of the market in Asia Pacific. Japan and Australia are other major contributor to the market growth in this region.
Intended Audience
- Pharmaceutical Companies
- Pharmaceutical Suppliers
- Cancer Research Organizations
- Potential Investors
- Key Executive (CEO and COO) and Strategy Growth Manager
- Research Companies
Frequently Asked Questions (FAQ) :
The projected CAGR of Asia Pacific Cancer Biological Therapy Market would 5.5% during the forecast period of 2018-2023.
The Asia Pacific Cancer Biological Therapy Market could be deterred by the high cost involved in the process.
The players are F. Hoffmann-La Roche Ltd (Switzerland), Merck & Co., Inc. (US), Bristol-Myers Squibb (US), Novartis AG (Switzerland), Amgen Inc. (US), Pfizer (US), Intas Pharmaceuticals Ltd. (India), Eli Lilly and Company (US), EnGeneIC (Australia), Celgene (US), and Sun Pharmaceutical Industries Ltd. (India).
Asia Pacific Cancer Biological Therapy Market segmented by types into interferon, monoclonal antibodies, cancer growth inhibitors, interleukins, colony-stimulating factors, gene therapy, cancer vaccines, targeted therapy, and others.
Asia Pacific Cancer Biological Therapy Market segmented by end users into laboratories, cancer research centers, hospitals & clinics, and others.
